Literature DB >> 35772460

Optimal molecular selection to benefit from nivolumab-ipilimumab in clear-cell renal cell carcinoma.

Yann-Alexandre Vano1, Réza Elaidi2, Letuan Phan2, Wolf Herman Fridman3, Catherine Sautès-Fridman3, Stéphane Oudard4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35772460     DOI: 10.1016/S1470-2045(22)00331-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   54.433


× No keyword cloud information.
  1 in total

1.  Tailoring treatment in metastatic renal cell carcinoma.

Authors:  Eduard Roussel; Benoit Beuselinck; Maarten Albersen
Journal:  Nat Rev Urol       Date:  2022-06-09       Impact factor: 16.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.